Wedbush restated their outperform rating on shares of Stemline Therapeutics Inc (NASDAQ:STML) in a research note issued to investors on Saturday. They currently have a $11.00 price target on the biopharmaceutical company’s stock.
STML has been the topic of a number of other research reports. HC Wainwright set a $34.00 target price on Stemline Therapeutics and gave the company a buy rating in a research note on Monday, March 20th. Roth Capital restated a buy rating and issued a $32.00 target price on shares of Stemline Therapeutics in a research note on Wednesday, December 7th. Ladenburg Thalmann Financial Services set a $41.00 target price on Stemline Therapeutics and gave the company a buy rating in a research note on Monday, March 20th. Zacks Investment Research downgraded Stemline Therapeutics from a hold rating to a sell rating in a research note on Wednesday, January 18th. Finally, Cowen and Company restated a buy rating on shares of Stemline Therapeutics in a research note on Thursday, March 23rd. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Stemline Therapeutics currently has a consensus rating of Buy and a consensus price target of $24.33.
Shares of Stemline Therapeutics (NASDAQ:STML) traded down 2.81% during midday trading on Friday, reaching $8.65. 96,674 shares of the company’s stock traded hands. Stemline Therapeutics has a 52 week low of $4.79 and a 52 week high of $14.60. The company’s market capitalization is $155.28 million. The stock’s 50 day moving average is $8.70 and its 200-day moving average is $10.40.
COPYRIGHT VIOLATION NOTICE: “Stemline Therapeutics Inc (STML) Stock Rating Reaffirmed by Wedbush” was originally published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.chaffeybreeze.com/2017/04/21/stemline-therapeutics-stml-outperform-rating-reaffirmed-at-wedbush-updated-updated.html.
In related news, insider David Gionco sold 6,486 shares of the business’s stock in a transaction dated Tuesday, February 28th. The stock was sold at an average price of $6.99, for a total transaction of $45,337.14. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Kenneth Hoberman sold 4,000 shares of the business’s stock in a transaction dated Monday, February 27th. The stock was sold at an average price of $6.97, for a total value of $27,880.00. The disclosure for this sale can be found here. Insiders have sold a total of 52,653 shares of company stock valued at $364,803 in the last three months. 16.70% of the stock is owned by insiders.
A number of institutional investors have recently bought and sold shares of the stock. Acadian Asset Management LLC purchased a new position in Stemline Therapeutics during the third quarter valued at approximately $400,000. State Treasurer State of Michigan bought a new position in shares of Stemline Therapeutics during the third quarter worth about $217,000. Oak Ridge Investments LLC boosted its position in shares of Stemline Therapeutics by 26.3% in the third quarter. Oak Ridge Investments LLC now owns 12,796 shares of the biopharmaceutical company’s stock worth $139,000 after buying an additional 2,663 shares during the last quarter. Columbus Circle Investors bought a new position in shares of Stemline Therapeutics during the third quarter worth about $1,577,000. Finally, Baker BROS. Advisors LP bought a new position in shares of Stemline Therapeutics during the third quarter worth about $3,612,000. 37.76% of the stock is owned by hedge funds and other institutional investors.
About Stemline Therapeutics
Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.
Receive News & Ratings for Stemline Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.